Immutep Limited American Depositary Shares (IMMP)

FairStock Score: 41/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable competitive advantages, predictable earnings, and a margin of safety. Immutep is a clinical-stage biotechnology company developing LAG-3 immunotherapies, including eftilagimod alfa and AIPAC-003 for metastatic breast cancer. That is not a business I can value with the tools Graham taught me: it has no revenue or profit growth history in the data, and FairStock's Lynch category is none because there are only 0 years of filed results where 3 are needed. FairStock's return metrics are poor: ROE is -77.31%, ROCE is -42.45%, and its P/E is -9.39 as of the 2026-10-13 close. The Piotroski F-Score is 2/9 and the Altman Z-Score is -5.48, which points to weak financial health and real distress risk. The one clear balance-sheet positive is low leverage, with D/E of 0.02. But at $3.57, FairStock's P/B is 11.90, so the market is paying a rich price for book value while earnings are negative. Beta is 2.20, and the 52-week range of $0.26 to $4.87 shows how violently sentiment can swing. The FairStock Score is 41/100. Growth depends on clinical trial outcomes, not on an established earnings stream. As a value investor, I see speculative pipeline risk, no demonstrated moat, and no margin of safety in these figures. The price may reflect hope, but the numbers show a fragile, unproven enterprise.

In plain English: Immutep is a small clinical-stage biotech developing immunotherapy medicines for cancer and autoimmune diseases. It is not yet profitable, its financial health looks weak, and the stock price is high compared with its accounting value. Based on the numbers given, the shares look expensive for a business with no proven earnings record.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer